{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals Hits New 52-Week High of $18.39
Amneal Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting strong performance in the pharmaceuticals sector. With a market capitalization of USD 3,728 million, the company has seen significant stock price growth over the past year, despite challenges in its financial metrics and unique debt structure.
Amneal Pharmaceuticals Hits New 52-Week High at $17.76
Amneal Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting a substantial increase in stock performance over the past year. With a market capitalization of USD 3,728 million and a P/E ratio of 22.00, the company demonstrates a unique financial structure and notable market activity in the pharmaceuticals sector.
Amneal Pharmaceuticals Hits New 52-Week High of $16.73
Amneal Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, notably outperforming the S&P 500, despite having a negative return on equity and no dividend yield.
Amneal Pharmaceuticals Hits New 52-Week High of $16.34
Amneal Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant growth over the past year, outpacing broader market gains, and demonstrates a robust market position despite certain financial metrics indicating challenges.
Amneal Pharmaceuticals Hits Day High with Strong 7.15% Intraday Surge
Amneal Pharmaceuticals, Inc. has seen notable stock performance, with a 7.15% increase on June 9, 2026, and a 93.04% rise over the past year. Despite challenges like a negative book value, the company has reported significant net profit growth and maintains strong institutional holdings.
Amneal Pharmaceuticals Hits New 52-Week High of $10.70
Amneal Pharmaceuticals, Inc. achieved a new 52-week high of USD 10.70 on October 30, 2025, reflecting a 45.99% growth over the past year. The company, with a market capitalization of USD 3,056 million, operates in the Pharmaceuticals & Biotechnology industry and exhibits unique financial metrics.
Amneal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance
Amneal Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The company’s stock price has shown resilience, with a notable year-to-date return of 33.21%. Over the past year, it has outperformed the S&P 500, reflecting its strong recovery and growth trajectory in the pharmaceuticals sector.
Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Amneal Pharmaceuticals shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite some short-term weakness indicated by the weekly RSI, and has significantly outperformed the S&P 500 over three years.
Amneal Pharmaceuticals Hits New 52-Week High of $10.67
Amneal Pharmaceuticals, Inc. achieved a new 52-week high of USD 10.67 on October 3, 2025, reflecting a 51.68% growth over the past year. The company, with a market capitalization of USD 3,056 million, faces challenges such as negative return on equity and a significant debt-to-equity ratio.
Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Amneal Pharmaceuticals has a bullish technical trend, supported by positive MACD and Bollinger Bands signals, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 31.19% compared to 14.18%.
Amneal Pharmaceuticals Hits New 52-Week High of $10.43
Amneal Pharmaceuticals, Inc. achieved a new 52-week high of USD 10.43 on October 1, 2025, reflecting a significant increase from its previous low. The company has seen a 51.53% rise in stock price over the past year, outperforming the S&P 500, and has a market capitalization of USD 3,056 million.
Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of September 5, 2025, Amneal Pharmaceuticals, Inc. shows a bullish technical trend, supported by positive daily moving averages and a weekly MACD, despite some caution from mildly bearish monthly indicators, while outperforming the S&P 500 with a year-to-date return of 23.86%.
Is Amneal Pharmaceuticals, Inc. overvalued or undervalued?
As of March 1, 2024, Amneal Pharmaceuticals, Inc. is considered a risky investment due to its high P/E ratio of 51.39, overvaluation compared to industry peers, and recent stock volatility despite a year-to-date return of 23.86%.
Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of June 6, 2025, the trend is mildly bearish, influenced by daily moving averages and monthly indicators, despite some bullish signals from the weekly MACD and RSI, indicating a cautious outlook.
What does Amneal Pharmaceuticals, Inc. do?
Amneal Pharmaceuticals, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry. It currently has no dividend yield, and its financial metrics indicate significant negative values for debt equity and return on equity.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
